血管瘤组织中p63和Fos蛋白的定量表达

目的　探讨 p6 3基因和c fos基因的蛋白与血管瘤发生发展的关系。方法　采用免疫组织化学S P法对 4 0例血管瘤和 2 0例正常皮肤组织检测 p6 3基因和c fos基因的蛋白表达 ;对所获得的检测结果进行图像分析处理。结果　在正常皮肤组、增生期与消退期血管瘤中 ,p6 3和Fos蛋白的平均光密度分别为 :0 92 3± 0 191,0 0 79± 0 0 2 4 ;8 2 71±1 95 3,0 12 4± 0 0 15 ;0 92 0± 0 187,0 0 88± 0 0 17。增生期组与消退期组、正常皮肤组分别相比 ,p6 3和Fos阳性表达的差异均有显著性 (P <0 0 5 ) ,消退期组与正常皮肤组之间 ,p6 3阳性表达的差异无显著性 (P >0 0 5 )。结论　p6 3基因在血管瘤中并未作为肿瘤抑制基因起作用 ,相反是作为癌基因而促进内皮细胞的增殖 ,可能与血管形成关系密切。c fos在血管瘤的增生中起着重要作用 ,可能与c fos可通过识别bFGF启动子区的特异位点TRE而启动bFGF基因的转录有关。     

p63和p63参与p53依赖的细胞凋亡过程

人们通常用经典的操作式学习方法来训练动物的行为 ,使动物学会根据外部信号 (如声音 )产生特定的行为反应 ,以获取奖赏 (如食物 )。而本文的作者用脑内植入微电极进行脑区刺激的方法教会动物如何学习 ,可以去除用来产生信号和奖赏的外部环境对实验的限制。这一动物模型使操作者能远距离地指挥动物的行为 ,很像控制智能机器人的方法。电刺激能否产生等同于信号或奖赏的效应 ,取决于它所刺激的脑区。作者在自由活动大鼠的躯体感觉皮层 (ＳＩ)左右两侧胡须代表区和内侧前脑束 (ＭＦＢ)内植入电极加以刺激 ,以产生信号和奖赏效应 ,据此准确地指…     

结直肠癌组织RSK4、p53蛋白的表达及临床病理意义

目的:探讨结直肠癌组织中P90核糖体S6激酶4(RSK4)蛋白、p53蛋白的表达及其临床病理意义。方法:选取我院病理科2014年1月~2016年5月既往收集的结直肠癌手术后标本70例及同期结直肠癌癌旁组织30例,采用免疫组化染色检测两组标本中RSK4蛋白、p53蛋白的表达情况,并分析其与结肠癌患者临床病理特征的相关性。结果:结直肠癌组织中RSK4蛋白、p53蛋白的阳性表达率分别为20.00%、55.71%,而癌旁组织中RSK4蛋白、p53蛋白阳性表达率分别为53.33%、10.00%,两组比较差异均具有统计学意义(P0.05)。Ⅰ期+Ⅱ期、高分化和中分化结直肠癌组织RSK4蛋白的阳性表达率显著高于Ⅲ期、低分化结直肠癌(P0.05);Ⅰ期+Ⅱ期、浸润深度(T1、T2)、未发生淋巴结转移的结直肠癌组织中p53蛋白阳性表达率显著的低于Ⅲ期、浸润深度(T3、T4)、发生淋巴结转移的结肠癌组织(P0.05)。结论:结直肠癌组织中RSK4蛋白表达下调、p53蛋白表达上调,二者可能与结直肠癌的发生和发展有关,并可能作为结肠癌诊断和预后评估的参考指标。     

胃癌组织中p53、p21WAF1蛋白的表达及与幽门螺杆菌L型感染的关系研究

目的:研究胃癌组织中磷蛋白53(P53)、磷蛋白21野生型p53活化片段(p21WAF1)蛋白的表达及与幽门螺杆菌L型(Hp-L)感染的关系。方法:选择我院2013年1月至2017年1月病理确诊为胃癌的标本220例为胃癌组,另外选取胃癌组织旁的健康组织为对照组。Hp-L采用快速尿素酶测试法、Giemsa染色法检测,P53、p21WAF1阳性表达采用HE法及免疫组化法测定,并采用Spearman等级检验分析其相关性。结果:胃癌组p53阳性表达率显著高于对照组(P0.05);p21WAF1阳性表达率显著低于对照组(P0.05),胃癌组织中p53和p21WAF1表达呈负相关(P0.05)。胃癌组Hp-L阳性感染率显著高于对照组(P0.05);胃癌组Hp-L阳性组p53阳性表达率显著高于于阴性组(P0.05);p21WAF1阳性表达率显著低于阴性组(P0.05),胃癌组织中p53与Hp-L阳性表达呈正相关(P0.05),p21WAF1与Hp-L阳性表达呈负相关(P0.05),p53阳性表达仅与浸润程度有关(P0.05),P21WAF1表达与病理分级、浸润程度、UICC分期有关(P0.05)。结论:Hp-L是胃癌发生的主要诱因,癌症发展过程中,Hp-L型感染可上调p53表达、抑制p21WAF1表达,且p53、p21WAF1的表达变化与细胞浸润程度有密切联系,对胃癌的临床治疗具有重要作用。     

甲状腺肿瘤p53mRNA及p53蛋白表达的研究

本文采用原位杂交法、免疫组织化学方法分别检测了甲状腺癌ｐ５３ｍＲＮＡ、ｐ５３蛋白的表达,结果显示：２０例甲状腺癌ｐ５３ｍＲＮＡ、ｐ５３蛋白均呈阳性反应,８例甲状腺瘤仅１例呈弱阳性反应,８例Ｇｒａｖｅｓ病全部呈阴性反应。细胞质和细胞核ｍＲＮＡ、ｐ５３蛋白灰度检测发现,甲状腺瘤细胞质、核ｐ５３ｍＲＮＡ灰度值和ｐ５３蛋白灰度值均明显高于Ｇｒａｖｅｓ病,而甲状腺癌其细胞质、核ｐ５３ｍＲＮＡ灰度值和ｐ５３蛋白灰度值又明显高于良性甲状腺瘤,提示甲状腺癌ｐ５３ｍＲＮＡ和ｐ５３蛋白的高表达可能与甲状腺肿瘤细胞分化程度有关     

结肠癌中NMNAT2、p53的表达及三者相关性研究

目的:检测结肠癌中烟酰胺核苷酸腺苷转移酶2 (Nicotinamide nucleotide adenosine transferase 2, NMNAT2)、p53的表达并分析三者之间的关系。方法:免疫组化S-ABC法(4分为阴性、≥4分为阳性)检测结肠癌标本(48例)、癌旁正常组织标本(40例)中NMNAT2、p53的表达,分析其与结肠癌年龄、性别、病理类型、肿瘤形态、分化程度、浸润深度、TNM分期、淋巴结转移等临床参数的关系及二者的关系。结果:(1) NMNAT2、p53表达于结肠癌组织细胞质、胞核,呈棕黄或棕褐色,在癌旁正常组织中表达较低或缺失。结肠癌中NMNAT2、p53表达阳性者占83.33%、70.83%,癌旁正常组织中表达阳性者占7.50%、0.00%,其差异有统计学意义(P0.05)。(2) NMNAT2、p53阳性率,在不同年龄、性别、病理类型、肿瘤形态、分化程度患者中的差异无统计学意义(P0.05);(T3-T4)期者为96.51%、84.62%,高于(T1-T2)期的68.18%、54.55%(P0.05);(Ⅲ-Ⅳ)期者为95.00%、85.00%,高于(Ⅰ-Ⅱ)期的78.57%、57.14%(P0.05);有淋巴结转移者为100.00%、84.21%,高于无淋巴结转移者的72.41%、62.07%(P0.05)。(3)结肠癌组织中NMNAT2与p53表达呈正相关(rs=0.809, P0.05)。结论:NMNAT2、p53与结肠癌发展相关,且二者呈正相关,因此,联合检测有助于对结肠癌诊治与病情评估。     

p53、p63和Ki67与肌层浸润性膀胱癌预后的关系

目的 研究突变型p53、p63和Ki67的表达和肌层浸润性膀胱癌(muscle invasive bladder cancer,MIBC)预后的相关性.方法 回顾性收集2007年1月至2016年12月在我院因肌层浸润膀胱癌行根治性膀胱切除术患者共99例.根据突变型p53、p63和Ki67的表达情况将病人进行分组,采用K...     

胚胎期接触双酚A对雄鼠睾丸内PCNA和p53表达的影响

目的研究胚胎期接触双酚A(Bisphenol A,BPA)对雄性胎鼠睾丸发育的影响及睾丸内增殖细胞核抗原(Proliferating Cell Nuclear Antigen,PCNA)和p53表达的影响。方法母鼠怀孕后第2天对其灌服双酚A(剂量5,50,100 mg/ml/day),一直持续分娩,F1代雄性小鼠饲养至75日龄,观察BPA对仔鼠成年后睾丸结构和PCNA和p53表达的影响。结果发现BPA处理组睾丸发育受到抑制,曲细精管直径和管腔直径变小(P0.05),管腔内出现大量胞质残余体,部分管腔出现潴留管腔液,支持细胞生长受到抑制,生精细胞排列紊乱,细胞质出现空泡化。免疫组织化学结果显示在BPA处理组,PCNA除了在精原细胞大量表达外,在初级精母细胞中表达量明显升高(P0.05,P0.01),免疫荧光结果显示胚胎期接触BPA导致成年后睾丸内p53蛋白表达量显著升高(P0.05,P0.01)。结论胚胎期接触BPA对雄鼠睾丸发育有着长期的不良影响,可能源于BPA引起细胞的异常增殖和凋亡。     

p53突变蛋白在胃癌组织中的表达及免疫电镜观察

作者应用抗ｐ５３单克隆抗体Ｐａｂ１８０１（Ａｂ２美国癌基因公司产品）对３８例手术切除的胃癌组织及癌旁胃粘膜的冰冻切片标本进行ｐ５３突变蛋白表达的检测,并进一步用胶体全免疫电镜技术对ｐ５３突变蛋白的分布特征进行观察。结果：３８例胃癌组织中,２４例有ｐ５３突变蛋白高表达,阳性率６３．２％。在对应的癌旁胃粘膜中１０例为ｐ５３的弱表达,正常组织无表达。伴有淋巴结转移的２３例胃癌标本中,１８例ｐ５３高表达（７８．３％）。免疫电镜结果表现,ｐ５３蛋白主要分布于核内染色质中,胞浆中有散在的阳性区,但以核膜周边为主,紧靠核膜。本研究结果提承胃癌的发生及其肿瘤的生物学行为与抑癌基因ｐ５３的突变密切相关,ｐ５３突变蛋白可能是通过对ＤＮＡ复制的影响而参与肿瘤的形成。     

From p63 to p53 across p73

Most genes are members of a family. It is generally believed that a gene family derives from an ancestral gene by duplication and divergence. The tumor suppressor p53 was a striking exception to this established rule. However, two new p53 homologs, p63 and p73, have recently been described [1, 2, 3, 4, 5 and 6]. At the sequence level, p63 and p73 are more similar to each other than each is to p53, suggesting the possibility that the ancestral gene is a gene resembling p63/p73, while p53 is phylogenetically younger [1 and 2].

The complexity of the family has also been enriched by the alternatively spliced forms of p63 and p73, which give rise to a complex network of proteins involved in the control of cell proliferation, apoptosis and development [1, 2, 4, 7, 8 and 9].

In this review we will mainly focus on similarities and differences as well as relationships among p63, p73 and p53.     

p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53

p53 mutations, occurring in two-thirds of all human cancers, confer a gain of function phenotype, including the ability to form metastasis, the determining feature in the prognosis of most human cancer. This effect seems mediated at least partially by its ability to physically interact with p63, thus affecting a cell invasion pathway, and accordingly, p63 is deregulated in human cancers. In addition, p63, as an 'epithelial organizer', directly impinges on epidermal mesenchimal transition, stemness, senescence, cell death and cell cycle arrest, all determinant in cancer, and thus p63 affects chemosensitivity and chemoresistance. This demonstrates an important role for p63 in cancer development and its progression, and the aim of this review is to set this new evidence that links p63 to metastasis within the context of the long conserved other functions of p63.     

Differential effects of p63 mutants on transactivation of p53 and/or p63 responsive genes

p63, known to play a role in development, has more recently also been implicated in cancer progression. Mutations in p63 have been shown to be responsible for several human developmental diseases. Differential splicing of the p63 gene gives rise to p63 isoforms, which can act either as tumor suppressors or as oncogene. In this report, we studied the effects of naturally occurring TAp637 mutants on the regulation of p53/p63 and p63 specific target genes. We observed significant differences among p63 mutants to regulate the p53/p63 and p63 specific target genes. Additionally, we observed a differential effect of p63 mutants on wildtype-p63-mediated induction ofp53/p63 and p63 specific target genes. We also demonstrated that these mutants differentially regulate the binding of wildtype p63 to the promoter of target genes. Furthermore, the effects of these mutants on cell death and survival were consistent with their ability to regulate the downstream targets when compared to wildtype TAp63T. In summary, our data demonstrate that p63 mutants exhibit differential effects on p63 and p53/p63 specific target genes and on the induction of apoptosis, and provide further insight into the function of p63.     

Expression of Ki-67, p53 and p63 proteins in keratocyst odontogenic tumours: an immunohistochemical study

Aim To investigate the immunohistochemical expression of Ki-67, p53 and p63 in Keratocyst Odontogenic Tumours (KOTs) in order to contribute to the biological profile of this tumor. Methods Immunohistochemical technique was performed using the EnVision™ System in 37 cases of KOTs. Results Ki-67- and p53-immunostained cells were mainly located in the suprabasal layers. p63-positive cells were found throughout the lining cystic epithelium. No difference in the immunostaining for these proteins was observed between primary and recurrent KOTs (Ki-67: P = 0.5591; p53: P = 0.9847; p63: P = 0.9127), or between KOTs associated with Nevoid Basal Cell Carcinoma Syndrome (NBCCS) and sporadic KOTs (Ki-67: P = 0.7013; p53: P = 0.3197; p63: P = 0.2427). Conclusions It is possible that biological behavior of KOTs may be related to suprabasal proliferative compartment in the cystic epithelium as observed by high levels of Ki-67, p53 and p63. In addition, p63 immunostaining may represent immaturity of keratinocytes in KOTs, and suggests that this protein may participate in the regulation of epithelial cell differentiation. Taken together, these data may favor tumorigenesis on KOTs.     

A dominant negative form of p63 inhibits apoptosis in a p53-independent manner

Stem cells are a source of differentiated cells in multiple tissues. If genetic alterations occur in stem cells, the problem persists and malignant cancers may arise. DeltaNp63alpha-a homologue of the tumor suppressor p53-is exclusively expressed in proliferating undifferentiated epithelial cells and cancer cells of epidermal origin. Here, we show that DeltaNp63alpha antagonizes DNA damage-induced apoptosis in a p53-independent manner. We found that upon cellular injury, DeltaNp63alpha must be downregulated before apoptotic program can be activated. The 5637 cell line has abundant levels of DeltaNp63alpha and mutant p53, and it is resistant to DNA damage-induced apoptosis. The knockdown of DeltaNp63alpha by RNA interference sensitized these cells to apoptosis upon genotoxic insult. This suggests that DeltaNp63alpha plays an anti-apoptotic role regardless of the p53 status. Considering the frequent mutations of p53 in tumor cells, our results provide important implications for the treatment of cancers in which p63 is amplified.